Last reviewed · How we verify
undefined
undefined is a Small molecule drug developed by Institut Bergonié. It is currently in Phase 2 development. Also known as: Mouthwash Product.
Undefined is a medication studied in clinical trials for various conditions, including Hepatitis C Infection, HIV Infection, IBD, Crohn's Disease, and Ulcerative Colitis. The exact mechanism of undefined is unknown, as indicated by ChEMBL.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | undefined |
|---|---|
| Also known as | Mouthwash Product |
| Sponsor | Institut Bergonié |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
- Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
- Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
- Different Cryocompression Devices and Skin Temperature of the Knee (NA)
- Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
- Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
- Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PHASE2)
- CMR Imaging of Autoimmune Diseases
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- undefined CI brief — competitive landscape report
- undefined updates RSS · CI watch RSS
- Institut Bergonié portfolio CI
Frequently asked questions about undefined
What is undefined?
Who makes undefined?
Is undefined also known as anything else?
What development phase is undefined in?
Related
- Manufacturer: Institut Bergonié — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Mouthwash Product
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing